Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3352W HIGH $5.55
Volume
262.24 K
Value Traded
1.27 M
Short % Float
7.09%
-0.61%Week
-25.08%1 Month
-29.22%3 Month
-34.89%6 Month
-5.86%5 Year
-74.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
151.58 M
EPS (TTM)
-1.75
P/E Ratio
-
Ent. Value
3.07 M
Total Shares
61.58 M
Float Shares
51.59 M
Insiders
16.27%
Institutions
57.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VYGR Catalyst Timeline
Dated clinical, regulatory and corporate events for Voyager Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Voyager Therapeutics, Inc.
569Total events
6Upcoming
81Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Voyager CEO to participate in pre-recorded fireside chat at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
▲Oral PresentationVY1706Presentation
Late-breaking oral presentation of 3-month GLP toxicology data for VY1706 at ASGCT 2026
Alzheimer's diseasesource ↗
◆Poster PresentationPresentation
Poster presentation on ApoE4/ApoE2 gene therapy in ApoE4 humanized mice
Alzheimer's diseasesource ↗
◆Topline ReadoutVY7523Clinical Data
Initial tau PET imaging data from multiple ascending dose trial
Alzheimer's diseasesource ↗
◆Trial InitiationTrial
Two I.V.-delivered neuro gene therapies to enter clinic H2 2026
neurological diseasessource ↗
◆Timing GuidanceVY7523Presentation
VY7523 data in AD patients expected H2 2026
Alzheimer's Diseasesource ↗
▲IND Enabling CompleteVY1706Preclinical
VY1706 completed IND-enabling GLP toxicology
Alzheimer's diseasesource ↗
▲IND Enabling CompleteNBIB-233Preclinical
NBIB-233 completed IND-enabling GLP toxicology
Friedreich's ataxiasource ↗
◆AcquisitionCorporate
Closing of business combination with VERAXA Biotech AG expected, subject to Nasdaq listing approvals and other conditions
▼Equity OfferingCorporate
Approximately 99.67% of Class A shares redeemed, leaving ~$885,556 in trust account
▲AcquisitionCorporate
Voyager Acquisition Corporation shareholders approve business combination with VERAXA Biotech AG
◆AcquisitionCorporate
Voyager Acquisition Corporation business combination with VERAXA Biotech AG
▲Partnership / LicenseCorporate
Transition Bio and Voyager enter collaboration to discover small molecules targeting TDP-43
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathologysource ↗
▲Pipeline PrioritizationCorporate
APOE program added to pipeline; fourth asset in Alzheimer's disease franchise
Alzheimer's diseasesource ↗
▲Preclinical PoCPreclinical
Single IV injection of TRACER capsid with bifunctional payload reduces endogenous APOE4 and increases APOE2 in APOE4 knock-in mice
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Pre-recorded fireside chat at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
◆IND SubmissionIND
Anticipated IND filing for SOD1-ALS gene therapy program
SOD1 amyotrophic lateral sclerosis (ALS)source ↗
▲PublicationPresentation
Publication of ALPL-mediated BBB transport data in Molecular Therapy
◆Oral PresentationVY1706Presentation
Oral presentation on tau silencing gene therapy VY1706 at ASGCT 28th Annual Meeting
Alzheimer's diseasesource ↗
◆Poster PresentationPresentation
Poster presentations on anti-amyloid gene therapy and capsid enhancements at ASGCT
Alzheimer's diseasesource ↗
●Poster PresentationVY1706Presentation
Poster presentation of VY1706 preclinical data at AD/PD 2025
Alzheimer's diseasesource ↗
●Poster PresentationVY7523Presentation
Poster presentation of VY7523 preclinical data at AD/PD 2025
Alzheimer's diseasesource ↗
●Oral PresentationPresentation
Dr. Ferguson speaks on panels at AD/PD 2025
Alzheimer's diseasesource ↗
●IND SubmissionIND
IND filing expected for SOD1-ALS gene therapy candidate
SOD1-mutated amyotrophic lateral sclerosis (ALS)source ↗
▲IND Enabling CompleteVY1706Preclinical
VY1706 in IND-enabling studies; robustly reduced tau mRNA levels in NHP study
Alzheimer's diseasesource ↗
▲First Patient DosedVY7523Trial
VY7523 in clinical trial in Alzheimer's disease patients
Alzheimer's diseasesource ↗
▲Topline ReadoutVY7523Clinical Data
Positive topline SAD data for VY7523 in healthy volunteers
Alzheimer's diseasesource ↗
▲Trial InitiationVY7523Trial
MAD trial initiated in patients with early Alzheimer's disease
Alzheimer's diseasesource ↗
▼Program DiscontinuationVY9323DiscontinuedCorporate
Voyager to assess alternate payloads for SOD1 ALS gene therapy program; no longer anticipates IND filing for VY9323 in mid-2025
superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)source ↗
Past FDA Catalysts and PDUFA Decisions
How VYGR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | VY7523 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$18M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 86%
Micro Cap(rank 566 of 658)
Percentile Rank
Voyager Therapeutics, Inc. faces pipeline headwinds (24/100), with $246M risk-adjusted pipeline value, led by VY7523 in Alzheimer's Disease (AD) (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VY7523 Small moleculeNCT06874621 | Alzheimer's Disease (AD) | Phase 1 | ACTIVE NOT_RECRUITING | 52 | May 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every VYGR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VY1706 | Alzheimer's disease | 2026-05-13 | well tolerated; no adverse clinical pathology or histopathological findings up to the highest dose tested (5E13 vg/kg); reduced tau protein up to 64% in key brain regions of non-human primates (NHPs) at 13 weeks following a single IV dose; dose-dependent reductions of up to 51-75% MAPT mRNA; 48-64% tau protein in key brain regions at 13 weeks in NHPsRead More | Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sandrock AlfredDirector, Officer (President and CEO) | Sell | -11,511 472,549 held | $3.87 | 04/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VYGR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.4 % (-33.3 %) | 4.15 M | 1.19 M | 3.04% ( 35.00 K) |
VYGR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VYGR ranks across every disease it competes in
Competitive Position is a premium feature
See how VYGR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVYGR News
VYGRVoyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the 2026 Cantor Global Healthcare Conference. The company aims to highlight its innovative approaches to treating neurological diseases. A webcast of the Wells Fargo fireside chat will be available for investors.
Read more →VYGRVoyager Reports Second Quarter 2026 Financial and Operating Results
Voyager Therapeutics reported its second quarter 2026 financial results, highlighting the expected clinical data for VY7523 and VY1706 in Alzheimer's by Q4 2026. The company ended the quarter with a robust cash position of $149 million, providing a financial runway into 2028. This positions Voyager favorably for ongoing and future developments.
Read more →VYGR▼ -5.8%on this news
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics presented data on VY1706, showing it was well tolerated in a six-month GLP toxicology study. The study demonstrated a reduction in tau levels, which is significant for Alzheimer's disease research. The company plans to initiate a clinical trial for VY1706 in Alzheimer's disease by the second half of 2026.
Read more →VYGRVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Voyager Therapeutics announced that its investigational gene therapy VY1706 for Alzheimer's disease will be featured in a poster presentation at the Alzheimer's Association International Conference (AAIC) 2026. The therapy, which targets tau proteins, has received FDA clearance for clinical trials, with dosing expected to start in the second half of 2026. Preclinical studies show promising results in reducing tau levels and a favorable safety profile.
Read more →VYGRVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics, Inc. will present at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. CEO Alfred W. Sandrock, Jr. will participate in a pre-recorded fireside chat, which will be available on-demand starting June 15, 2026. The company focuses on leveraging genetics to treat neurological diseases and has a diverse pipeline targeting various conditions.
Read more →VYGRVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics announced that the FDA has approved its IND application for VY1706, a gene therapy aimed at reducing tau protein levels associated with Alzheimer's disease. The company plans to initiate a clinical trial in the second half of 2026, focusing on adults with early-stage Alzheimer's. Preclinical studies have shown substantial reductions in tau levels and a favorable safety profile, indicating potential promise for this innovative treatment approach.
Read more →VYGRVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics presented promising data on VY1706, a gene therapy for Alzheimer's disease, at the ASGCT 2026 Annual Meeting. The three-month GLP toxicology study showed that VY1706 was well tolerated in non-human primates and significantly reduced tau protein levels. The company is on track to submit an IND application in Q2 2026, with clinical trials expected to start in H2 2026.
Read more →VYGRVoyager Reports First Quarter 2026 Financial and Operating Results
Voyager Therapeutics reported its first quarter 2026 financial results, highlighting a strong cash position of $172 million that supports operations into 2028. The company is preparing for clinical entry of its tau silencing gene therapy, VY1706, expected in the second half of 2026. Additionally, they anticipate significant data on tau knockdown as a treatment approach for Alzheimer's disease.
Read more →VYGRVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced multiple presentations at the ASGCT 2026 Annual Meeting, highlighting their investigational gene therapy VY1706 for Alzheimer's disease. A late-breaking presentation will showcase three-month GLP toxicology data demonstrating the therapy's pharmacology and safety. The company plans to submit an IND application in Q2 2026, aiming for first-in-human dosing later in the year.
Read more →VYGR▼ -8.5%on this news· ran to -23% by day 3
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
Voyager Acquisition Corporation has obtained approval for its business combination with Veraxa Biotech AG, allowing the merger to proceed. Following the closing, the new entity is set to be listed on Nasdaq under the ticker 'VRXA'. Notably, approximately 99.67% of Voyager's Class A ordinary shares will be redeemed, leaving around $885,556 in the trust account. Veraxa specializes in developing next-generation antibody therapeutics, signifying a promising future for the combined firm.
Read more →VYGRVoyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
Voyager Acquisition Corporation has announced that 25,217,315 of its Class A ordinary shares were redeemed, amounting to approximately 99.67% of the total outstanding shares in relation to its business combination with VERAXA Biotech AG. Following the expected redemptions, around $885,556 will remain in the trust account, and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG. The merger is anticipated to establish the combined entity as a publicly traded company on NASDAQ under the symbol 'VRXA.' VERAXA aims to advance a pipeline of innovative antibody-based therapeutics.
Read more →VYGR▲ +5.4%on this news· ran to +28% by day 1shared move
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics has announced its fourth quarter and full year 2025 financial results, highlighting a transformative year for the company. Key developments include the anticipated clinical entry of VY1706 and expected clinical data for VY7523 in the second half of 2026. The company ended 2025 with a robust cash position that is projected to sustain operations through 2028. Furthermore, the advancement of the Voyager NeuroShuttle platform aims to enhance therapeutic delivery for neurological diseases.
Read more →VYGRLeveraging Genetics to Treat Neurological Diseases Corporate Deck / January 2026 2 | Forward - Looking Statements This presentation contains forward - looking statements for the purposes of the safe harbor provisions und
Voyager Therapeutics has outlined its strategic focus on leveraging genetics to treat neurological diseases, particularly Alzheimer's, in its January 2026 corporate presentation. The company emphasizes the achievement of key preclinical and clinical milestones as part of its development pipeline, including the introduction of therapies targeting tau protein. Although there are optimistic financial forecasts regarding milestone payments, Voyager acknowledges various inherent risks, including regulatory uncertainties and external competition. The firm is managing a solid cash position expected to last until 2028 to support its ongoing projects.
Read more →VYGRTransition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Transition Bio and Voyager Therapeutics have announced a collaboration to develop small molecules targeting TDP-43 for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Transition Bio will lead the discovery and optimization of these molecules, with Voyager having the option to license the program. The partnership includes an upfront payment and potential milestone payments totaling up to $500 million.
Read more →VYGRVoyager Reports Third Quarter 2025 Financial and Operating Results
Voyager Therapeutics reported its third quarter 2025 financial results, highlighting a robust cash position of $229 million, which supports operations through 2028. The company is advancing its multi-modality pipeline, including the introduction of the Voyager NeuroShuttle program and a collaboration with Transition Bio to develop small molecules for ALS and FTD. Upcoming milestones include anticipated clinical data for its tau-targeting programs.
Read more →VYGR▲ +6.5%on this news· ran to +26% by day 3
Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference
At the Citi 2025 Biopharma Back to School Conference, Voyager Therapeutics, Inc. (NASDAQ: VYGR) presented its strategic vision for leveraging genetics in treating neurological diseases. The company highlighted expectations for multiple clinical programs by 2026, with a focus on Alzheimer's treatments. Voyager aims to expand its gene therapy and antibody strategies while utilizing its TRACER capsid discovery platform for effective therapeutic delivery. Despite the optimism, forward-looking statements were accompanied by acknowledgment of various risks and uncertainties that could impact progress.
Read more →VYGRVoyager Reports Second Quarter 2025 Financial and Operating Results
Voyager Therapeutics has reported its second-quarter 2025 financial results, showcasing an extended cash runway projected to last until 2028. This extension positions the company to facilitate multiple upcoming clinical data read-outs and supports the integration of its fourth pipeline asset targeting Alzheimer's disease. Switching to financial specifics, while the firm incurred a net loss of $33,382, concerns remain due to increased operating losses compared to the previous year. However, the company is optimistic about future milestones, especially with a potential $2.6 billion in development-stage milestone payments.
Read more →VYGR▲ +6.3%on this news
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Voyager Therapeutics has launched a new program targeting apolipoprotein E (APOE) to treat Alzheimer's disease. This program utilizes a proprietary TRACER capsid to deliver a bifunctional payload that aims to decrease the expression of the high-risk APOE4 variant while increasing the protective APOE2 variant. The company plans to present early data from this program at a scientific meeting in 2025, further expanding its Alzheimer's pipeline.
Read more →About Voyager Therapeutics, Inc.
Headquarters75 HAYDEN AVENUE, LEXINGTON, MA, 02421
BIOPHARMAWATCH ELITE PLUS
Trade the next VYGR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime